As a classic AngII receptor antagonist, losartan inhibits the TGF‐β signaling pathway in cardiac fibroblasts in vitro and attenuates myocardial hypertrophy, fibrosis, and left ventricular remodeling in vivo [30–32]. The gene discussed is TGFB1; the disease is cardiac hypertrophy.